CIR Share Price

Open 0.30 Change Price %
High 0.31 1 Day 0.00 0.00
Low 0.30 1 Week 0.00 0.00
Close 0.31 1 Month 0.00 0.00
Volume 70000 1 Year 0.00 0.00
52 Week High 33.50
52 Week Low 30.88
CIR Important Levels
Resistance 2 0.32
Resistance 1 0.32
Pivot 0.31
Support 1 0.30
Support 2 0.30
ASX Australia Most Active Stocks
AGO 0.04 -20.00%
AGO 0.04 -20.00%
AGO 0.04 -20.00%
SDL 0.01 0.00%
SDL 0.01 0.00%
SDL 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
LYC 0.14 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
PIO 0.03 50.00%
PIO 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
PMQ 0.03 50.00%
EGL 0.04 33.33%
EGL 0.04 33.33%
CHZ 0.05 25.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
TMX 0.01 -50.00%
GDY 0.01 -50.00%
CSV 0.46 -33.33%
CSV 0.46 -33.33%
CSV 0.46 -33.33%
More..

Circadian Technologies Ltd (ASX: CIR)

CIR Technical Analysis 4
As on 11th Dec 2015 CIR Share Price closed @ 0.31 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.19 & Buy for SHORT-TERM with Stoploss of 0.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
CIR Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CIR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.circadian.com.au
CIR Address
CIR
650 Chapel Street
Suite 0403
South Yarra, VIC 3141
Australia
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
CIR Latest News
Opthea Completes Patient Enrolment in Phase 1/2A wet AMD Clinical Trial   Marketwired (press release)   - 21st Nov 16
11 ASX Pharmaceutical Stocks: An Investor's Introduction   Investing News Network (press release) (registration) (blog)   - 27th Sep 16
How To Protect Yourself When The ASX Market Bear Roars Again   Daily Reckoning - Australian Edition   - 14th Sep 16
Retina Treatment Adverse Events to Take Center Stage at ASRS   Medscape   - 06th Aug 16
Is Opthea Ltd a buy on today's results?   Motley Fool Australia   - 26th Jul 16
Opthea Doses First Patient in Phase 2A Dose Expansion Study for OPT-302 in Wet AMD   Marketwired (press release)   - 05th May 16
Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective   Marketwired (press release)   - 21st Apr 16
Opthea Completes Patient Enrolment for OPT-302 Phase 1 Dose Escalation Trial ...   Marketwired (press release)   - 31st Mar 16
Opthea Signs Cell Line Development Commercial License Agreement with Selexis ...   PR Newswire (press release)   - 14th Jan 14
Circadian Technologies looks to royalties on cancer diagnostic test with ...   Proactive Investors Australia   - 10th Oct 11
Interactive Technical Analysis Chart Circadian Technologies Ltd ( CIR ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Circadian Technologies Ltd
CIR Business Profile
Circadian Technologies Limited develops and commercializes therapies for cancer and eye diseases in Australia. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets. The company’s product pipeline includes anti-VEGFR-3 antibody that is in Phase I clinical trials for the treatment of solid tumours; VGX-100, a human antibody against VEGF-C, as a treatment for lymphedema resulting from breast cancer treatment and solid tumours; and VGX-300, a soluble form of VEGFR-3 for ‘back of the eye’ disease. It also develops diagnostic test products for cancers of unknown primaries; and blood based diagnostic tests for VEGF-C and VEGF-D as predictive and prognostic tests in lymphangioleiomyomatosis and cancer patients. The company is based in South Yarra, Australia.